Advertisement
Canada markets close in 3 hours 56 minutes

  • S&P/TSX

    22,381.53
    +122.37 (+0.55%)
     

  • S&P 500

    5,199.65
    +11.98 (+0.23%)
     

  • DOW

    39,226.39
    +170.00 (+0.44%)
     

  • CAD/USD

    0.7305
    +0.0017 (+0.24%)
     

  • CRUDE OIL

    78.96
    -0.03 (-0.04%)
     

  • Bitcoin CAD

    85,076.50
    -59.33 (-0.07%)
     

  • CMC Crypto 200

    1,335.72
    +35.62 (+2.74%)
     

  • GOLD FUTURES

    2,336.40
    +14.10 (+0.61%)
     

  • RUSSELL 2000

    2,065.08
    +9.95 (+0.48%)
     

  • 10-Yr Bond

    4.4850
    -0.0070 (-0.16%)
     

  • NASDAQ

    16,319.32
    +16.56 (+0.10%)
     

  • VOLATILITY

    13.13
    +0.13 (+1.00%)
     

  • FTSE

    8,381.35
    +27.30 (+0.33%)
     

  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     

  • CAD/EUR

    0.6778
    +0.0002 (+0.03%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS DOW EYES EXTENDING 6-DAY WIN STREAK

U.S. jobless claims hit highest level since August 2023

Why Dynavax Technologies Stock Sank in September

George Budwell, The Motley Fool
·2 min read
Why Dynavax Technologies Stock Sank in September

Shares of the small-cap biotech Dynavax Technologies (NASDAQ: DVAX) lost 22.4% of their value during the month of September, according to data provided by S&P Global Market Intelligence. Dynavax's stock appears to have fallen victim to nothing more than speculators moving on to greener pastures. CpG 1018 is the same adjuvant used in the biotech's FDA-approved hepatitis B vaccine, Heplisav-B. Dynavax is currently collaborating with multiple partners to evaluate this commercial-stage adjuvant as part of a COVID-19 vaccine.

Continue reading